Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
IMWG real-world analysis of talquetamab for RRMM finds skin tox 39.7%, nail 75.5%, dysgeusia 60.4%, oral tox 62.9%; platelets <50 (HR 1.8, 95% CI 1.15-2.83) assoc w/ inferior PFS; ORR 67.6%, PFS 7 months, 12-month OS 65%.”
Title: Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis
Authors: Murali Janakiram, Carlyn R. Tan, Hira Mian, Chiung-Yu Huang, Rakesh Popat, Joaquín Martínez-Lopez, Efstathios Kastritis, Wee-Joo Chng, Prashant Kapoor, Mrugakshi Dave, Susan Bal, Laurent Garderet, Andre De Menezes Silva Corraes, Christine Riedhammer, Torsten Steinbrunn, Magdalene Corona, Chandramouli Nagarajan, Hermann Einsele, Tom Martin, Amrita Krishnan, Yi Lin
You can read the Full Article in American Journal of Hematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
